RxDoctor Payments DataLook up a doctor →

Amer Zeidan

Hematology & Oncology · New Haven, CTNPI 1083819528

Payments from drug & device makers

$15,497,189in general payments, 2019–2025

Across 1,432 payments — averaging $10,822 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$6.5M
  • Bristol Myers Squibb$1.4M
  • Novartis$1.2M
  • AbbVie$1.1M
  • Taiho Oncology, Inc.$1M
  • E.r. Squibb & Sons, L.L.C.$886K
  • plus $3.4M from 36 others
$46,354in research payments, 2019–2025

Across 28 payments — averaging $1655.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$13K
  • Bristol Myers Squibb$8K
  • Pfizer$8K
  • F. Hoffmann-la Roche AG$8K
  • AbbVie$6K
  • Astellas Pharma Global Development$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck8$6,486,103
Bristol Myers Squibb95$1,404,951
Novartis65$1,156,850
AbbVie160$1,121,719
Taiho Oncology, Inc.214$1,002,806
E.r. Squibb & Sons, L.L.C.34$885,765
Otsuka Pharmaceutical Co., Ltd.117$789,640
Pfizer(2 entities)59$640,253
Daiichi Sankyo Inc.320$413,540
Incyte Corporation50$348,098
Astellas Pharma Global Development17$291,780
Agios Pharmaceuticals, Inc.61$277,956
Takeda Pharmaceuticals U.S.A., Inc.32$149,286
Biocryst Pharmaceuticals, Inc.7$116,625
PTC Therapeutics, Inc.7$114,853
Geron Corporation83$83,161
Chiesi USA, Inc.11$53,940
Jazz Pharmaceuticals Inc.15$17,465
Epizyme, Inc.2$16,800
AstraZeneca2$13,908
Sumitomo Pharma America, Inc.3$10,793
Regeneron14$10,232
Gilead8$10,053
Amgen4$9,952
GSK5$8,800
Boehringer Ingelheim International GmbH3$7,982
Janssen Research & Development, LLC1$7,150
Boehringer Ingelheim1$6,750
Hikma Pharmaceuticals USA3$6,540
Rigel Pharmaceuticals, Inc.2$6,508
Genentech USA, Inc.7$6,418
Karyopharm Therapeutics Inc.1$4,890
Servier Pharmaceuticals LLC3$4,708
Kyowa Kirin, Inc.2$3,925
Beigene USA, Inc.2$2,062
Otsuka Pharmaceutical Development & Commercialization, Inc.6$2,057
Syndax Pharmaceuticals, Inc.3$1,943
Boehringer Ingelheim Pharma GmbH & Co.kg1$623
Seagen Inc.1$134
Astellas Pharma US Inc1$110
CTI Biopharma Corp.1$45
Kyowa Kirin Co., Ltd1$17

How this compares

$15,497,189 in reported general payments places this provider in the 95th percentile of 163 hematology & oncology providers in Connecticut.

See all hematology & oncology providers in Connecticut →

Medicare billing

Part B allowed, 2024
$33,471
Medicare patients
76
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in New Haven

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →